Michael McDonnell compensation by year
BIOGEN Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $294,231 | $868,798 | $901,308 | $945,268 | $992,531 | $226,895 |
| Bonus | $1,000,000 | $0 | $0 | — | — | $0 |
| Stock awards | $5,012,308 | $4,062,291 | $5,083,295 | $4,960,629 | $4,433,862 | $0 |
| Option awards | $0 | $0 | $0 | — | — | $0 |
| Non-equity incentive | $263,322 | $836,400 | $1,107,638 | $1,129,183 | $1,211,989 | $0 |
| Pension and deferred compensation | $0 | $513 | $2,538 | $837 | $1,056 | $0 |
| All other | $5,696 | $150,369 | $115,055 | $131,684 | $187,296 | $43,955 |
| Total | $6,575,557 | $5,918,371 | $7,209,834 | $7,167,601 | $6,826,734 | $270,850 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOGEN INC. DEF 14A filed April 28, 2026, accession 0001193125-26-187303, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIOGEN INC. filed document, accession 0001193125-26-187303. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 6,650 | $1,016,918 | — |
| RSU | 4,990 | $763,071 | — |
| RSU | 4,670 | $714,136 | — |
| RSU | 3,503 | $535,679 | — |
| RSU | 3,257 | $498,060 | — |
| RSU | 2,495 | $381,535 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIOGEN INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
BIOGEN’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Christopher Viehbacher | President and Chief Executive Officer | $23,646,004 |
| Susan Alexander | Executive Vice President, Chief Legal Officer | $8,132,517 |
| Nicole Murphy | Head of Pharmaceutical Operations and Technology | $7,575,505 |
| Priya Singhal | Head of Development | $7,571,387 |
| Robin Kramer | Executive Vice President and Chief Financial Officer | $5,806,584 |
| Michael McDonnell · this page | Former Executive Vice President and Chief Financial Officer | $270,850 |
Michael McDonnell's compensation dossier, BIOGEN
You have read Michael McDonnell's totals and holdings. The dossier adds each equity grant BIOGEN disclosed for Michael McDonnell and BIOGEN's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full BIOGEN compensation record
free company briefThis page is one person within BIOGEN's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIOGEN proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIOGEN's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOGEN's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BIIB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.